Cutler Group’s Cymabay Therapeutics CBAY Stock Holding History

Cutler Group’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$23K	–	3933
2023 Q4	$23K	Buy	+10,000	New	+$178K	﹤0.01%	1905
2019 Q3	–	Sell	-9,600	Closed	-$2K	–	4852
2019 Q2	$2K	Buy	9,600 +7,900	+465%	+$89.5K	﹤0.01%	3699
2019 Q1	$9K	Buy	+1,700	New	+$18.1K	﹤0.01%	2592
2018 Q3	–	Sell	-5,200	Closed	-$5K	–	4855
2018 Q2	$5K	Buy	5,200 +4,700	+940%	+$58.8K	﹤0.01%	3166
2018 Q1	$2K	Hold	500	–	–	﹤0.01%	3886
2017 Q4	$1K	Buy	+500	New	+$4.27K	﹤0.01%	4650

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cutler Group's CBAY Position: Q4 2023 in Review

Cutler Group sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 200 shares — an estimated $3.56K sold.

Cutler Group first reported a position in CBAY in Q4 2017 and held it in 10 quarters. The position peaked at $37K in Q2 2019. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Cutler Group reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 200 Cymabay Therapeutics shares in Q4 2023, an estimated $3.56K.
Cutler Group first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 10 quarters.
Cutler Group's Cymabay Therapeutics position peaked at $37K in Q2 2019.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.